Nektar Therapeutics (NKTR) Receives $48.18 Average Target Price from Analysts

Nektar Therapeutics (NASDAQ:NKTR) has earned an average rating of “Buy” from the sixteen research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $48.18.

A number of research firms have commented on NKTR. Canaccord Genuity restated a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Mizuho restated a “buy” rating and issued a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Zacks Investment Research lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub lowered shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 8th. Finally, Jefferies Group restated a “buy” rating and issued a $35.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, November 8th.

Nektar Therapeutics (NKTR) traded up $1.39 during trading hours on Wednesday, reaching $89.60. 1,290,000 shares of the company’s stock were exchanged, compared to its average volume of 2,970,000. The firm has a market capitalization of $14,330.00, a price-to-earnings ratio of -126.20 and a beta of 2.04. Nektar Therapeutics has a 52-week low of $12.50 and a 52-week high of $99.02. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.

In related news, CEO Howard W. Robin sold 83,333 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the completion of the sale, the chief executive officer now directly owns 272,768 shares of the company’s stock, valued at $15,190,449.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Stephen K. Doberstein sold 2,426 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $201,212.44. Following the sale, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at $5,589,658.36. The disclosure for this sale can be found here. Insiders have sold 222,781 shares of company stock worth $14,884,901 over the last quarter. 6.10% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of NKTR. California Public Employees Retirement System raised its stake in shares of Nektar Therapeutics by 2.2% during the second quarter. California Public Employees Retirement System now owns 190,900 shares of the biopharmaceutical company’s stock worth $3,732,000 after buying an additional 4,100 shares during the last quarter. State Street Corp raised its stake in shares of Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after buying an additional 447,023 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Nektar Therapeutics by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 114,357 shares of the biopharmaceutical company’s stock worth $2,235,000 after buying an additional 3,683 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Nektar Therapeutics by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 929 shares during the last quarter. Finally, Strs Ohio raised its stake in shares of Nektar Therapeutics by 16.3% during the third quarter. Strs Ohio now owns 16,400 shares of the biopharmaceutical company’s stock worth $393,000 after buying an additional 2,300 shares during the last quarter. 96.23% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/24/nektar-therapeutics-nktr-receives-48-18-average-target-price-from-analysts.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply